MedTrace Logo

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

NCT07674745 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-07-01

No results posted yet for this study

Summary

This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).

Conditions

Interventions

OTHER

Therapeutic Plasma Exchange

Removal of patient's plasma by mechanical means and replacement with saline and albumin or normal plasma

DRUG

Rituximab

Infusion of humanized mouse monoclonal antibody with specificity for human CD20

DRUG

Intravenous immunoglobulin

intravenous infusions of normal human immunoglobulin

DRUG

Treatment as Usual

Continued therapy with conventional, approved, specific IPF medications

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Steven R Duncan, MD · University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2030-09-30
Completion
2031-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07674745 on ClinicalTrials.gov